Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6359398 | 0.99 | PDE5A (0.98) | PDE5APDE6C | |
| SCHEMBL2404254 | 0.96 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL7616279 | 0.94 | PDE5A (0.89) | PDE5APDE6C | |
| SCHEMBL6777553 | 0.93 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL6360061 | 0.92 | PDE5A (0.84) | PDE5APDE6C | |
| SCHEMBL6358922 | 0.91 | PDE5A (0.85) | PDE5APDE6C | |
| SCHEMBL6359521 | 0.90 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL6772837 | 0.89 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL6776828 | 0.89 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL6771870 | 0.88 | PDE5A (1.00) | PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 882 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060123-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2021-03-04 | — | — | US | claimed |
| US-20180161392-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2018-06-14 | — | — | US | claimed |
| US-20180036314-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | EXODOS LIFE SCIENCES LP (US) | 2018-02-08 | — | — | US | claimed |
| EP-2825208-B1 | P75NTR NEUROTROPHIN BINDING PROTEIN FOR THERAPEUTIC USE | LEVICEPT LTD (GB) | 2017-05-17 | — | — | EP | claimed |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| US-20150037335-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2015-02-05 | — | — | US | claimed |
| US-20150031704-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | EXODOS LIFE SCIENCES LIMITED PARTNERSHIP | 2015-01-29 | — | — | US | claimed |
| EP-2175728-B1 | SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2014-09-10 | — | — | EP | claimed |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | claimed |
| US-20130053393-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | EXODOS LIFE SCIENCES LIMITED PARTNERSHIP (US) | 2013-02-28 | — | — | US | claimed |
| US-20030018037-A1 | Use of PDE V inhibitors for improved fecundity in mammals | SIMON LEMPRIERE WESTBROOK (GB) | 2003-01-23 | — | — | US | claimed |
| US-20020173502-A1 | Pharmaceutically active compounds | PFIZER INC | 2002-11-21 | — | — | US | claimed |
| US-20020165237-A1 | Treatment of the insulin resistance syndrome | PFIZER INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002072586-A1 | PYRAZOLO'4,3-D-PYRIMIDINE FOR INHIBITING CGMP PDE | PFIZER LIMITED (GB) | 2002-09-19 | — | — | WO | claimed |
| US-20020091129-A1 | Treatment of premature ejaculation | BOOLELL MITRADEV (GB) | 2002-07-11 | — | — | US | claimed |
| EP-1199070-A2 | Use of PDE V inhibitors for improved fecundity in mammals | Pfizer Limited (GB) | 2002-04-24 | — | — | EP | claimed |
| US-20020028799-A1 | Treatment of male sexual dysfunction | PFIZER INC. | 2002-03-07 | — | — | US | claimed |
| WO-2002013798-A2 | TREATMENT OF THE INSULIN RESISTANCE SYNDROME WITH SELECTIVE CGMP PDE5 INHIBITORS | PFIZER LIMITED (GB) | 2002-02-21 | — | — | WO | claimed |
| WO-2002003995-A2 | TREATMENT OF MALE SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2002-01-17 | — | — | WO | claimed |
| EP-1157705-A2 | Use of a phosphodiesterase inhibitor in the manufacture of a medicament for blood pressure stabilization during hemodialysis | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028799-A1 | Treatment of male sexual dysfunction | MME, PDE5A, PREP | PDE5A 2/4885PDE6C 91/4885 |
| US-20020173502-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE3B | PDE5A 1/4885PDE6C 20/4885 |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | PDE5A 27/4885PDE6C 166/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | PDE5A 27/4885PDE6C 166/4885 |
| US-20020165237-A1 | Treatment of the insulin resistance syndrome | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE6C 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.